Formulation Development of a Polymer-Drug Matrix with a Controlled Release Profile for the Treatment of Glaucoma
Glaucoma is the leading cause of blindness in the United States accounting for 9-12% of all cases of blindness. Currently, the front line treatment for glaucoma are prostaglandins that may have to be taken up to several times a day. Even with proper treatment, roughly 11% of the patients using the t...
| Main Author: | |
|---|---|
| Format: | Others |
| Published: |
DigitalCommons@CalPoly
2013
|
| Subjects: | |
| Online Access: | https://digitalcommons.calpoly.edu/theses/1134 https://digitalcommons.calpoly.edu/cgi/viewcontent.cgi?article=2239&context=theses |